Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Vasculitis
•
Relapsing polychondritis
•
Aortitis
In a young patient with relapsing polychondritis and aortitis which has led to severe aortic valve regurgitation, is there any preference for a mechanical versus bioprosthetic valve replacement?
Related Questions
How long do you continue rituximab in patients with ANCA associated vasculitis who have achieved remission?
How would you manage a patient on tocilizumab for recently diagnosed severe GCA who developed a bowel obstruction several weeks after the first dose of Tocilizumab?
How would you manage a patient with severe Hurley Stage 3 active, draining, HS who is also currently requiring Rituxan for management of vasculitis?
How soon after starting treatment for Takayasu arteritis do you decide on the need for any vascular interventions to manage chronic damage?
What is your approach to treatment of airway involvement, such as recurrent bronchial stenosis, in relapsing polychondritis?
How would you approach management of a patient with mixed cryoglobulinemic vasculitis with predominant skin involvement and no major organ involvement?
How would you approach EGPA with renal involvement that was on maintenance Rituximab, last infusion two months ago and develops new onset liver involvement?
How do you approach confirming a diagnosis of limited GPA with nasal involvement vs relapsing polychondritis?
How would you approach the treatment for patients with renal-limited ANCA vasculitis who have persistent proteinuria, hematuria, and ANCA titers and have completed a steroid taper and received three doses of rituximab?
Would you consider tocilizumab for treatment of GCA in patients with underlying CLL (not requiring therapy)?
